- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01520805
Safety and Effectiveness Study of CPI-613 to Treat Refractory or Relapsed Leukemia and Myelodysplastic Syndrome
A Phase 2a Open-Label Clinical Trial Evaluating Efficacy & Safety of CPI-613 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML), and in Patients With Myelodysplastic Syndrome (MDS) Who Failed Hypomethylating Agents
Study Overview
Status
Intervention / Treatment
Detailed Description
A new therapy for AML is necessary because, although there are several treatment options for patients with AML, these treatments are very toxic and not available to all AML patients or only useful for acute promyelocytic leukemia (APL). Also, there is essentially no treatment for patients with refractory or relapsed AML outside of bone marrow transplant. Accordingly, there is a great medical need for a safe and effective therapy for AML, especially refractory and relapsed AML. Also, although hypomethylating agents have been found to be effective against MDS, these agents are toxic. Furthermore, after relapsing from a hypomethylating agent, there is no treatment for this disease.
A nearly completed clinical trial of CPI-613 (Cornerstone Study# CL-CPI-613-009 or Wake Forest Study# CCCWFU 29109, under IND# 107,800) shows that CPI-613 is well tolerated at doses as high as 3,000 mg/m2. Results from this nearly completed trial also suggest that CPI- 613 may be effective against refractory and relapsed AML, as well as against MDS that is relapsed from a hypomethylating agent. Therefore, CPI-613 may be a suitable treatment option for refractory/relapsed AML and MDS relapsed from a hypomethylating agent. The promising preliminary efficacy data from Study# CL-CPI-613-009 (Wake Forest Study# CCCWFU 29109, under IND# 107,800) is the basis on which Cornerstone is conducting the current Phase 2a trial to further assess the efficacy of CPI-613 against these diseases.
Study Type
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
New Jersey
-
Cranbury, New Jersey, United States, 08512
- Cornerstone Pharmaceuticals, Inc
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Have either documented refractory or relapsed AML, or documented MDS of any risk group that has failed a hypomethylating agent (such as decitabine [Vidaza] and azacitidine [AZA]). (Therapy failure with a hypomethylating agent is defined as patients who have been sufficiently treated with hypomethylating agents without response in the opinion of the treating physician, or whose disease has progressed or relapsed while on a hypomethylating agent.) Has never been treated with CPI-613.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
- Expected survival >2 months.
- 18 years of age and older of both genders.
- Women of child-bearing potential (i.e., women who are pre-menopausal or not surgically sterile) must use accepted contraceptive methods (abstinence, intrauterine device [IUD], oral contraceptive, or double barrier device) during the study, and must have a negative serum or urine pregnancy test within 1 week prior to treatment initiation.
- Fertile men must practice effective contraceptive methods during the study, unless documentation of infertility exists.
- No radiotherapy, surgery or hormonal therapy for any kind of within 2 weeks prior to participating in this study. Patients must have fully recovered from the acute toxicities of any prior treatment with any anti-cancer drugs (including hypomethylating agents in MDS patients), radiotherapy or other anti-cancer modalities (i.e., returned to baseline status as noted before most recent treatment) for any tumors. Patients with persisting, stable chronic toxicities from such prior treatment ≤Grade 1 are eligible, but must be documented as such.
- Recombinant erythropoietin or G-CSF is not allowed, since CPI-613 does not induce myelosuppression.
- No evidence of active or serious infection of any kind within the past month. No systemic fungal, bacterial, viral or other infection not controlled, defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment.
- Signed informed consent form.
Exclusion Criteria:
- Serious medical illness, such as significant cardiac disease (e.g. symptomatic congestive heart failure, unstable angina pectoris, myocardial infarction within the past 6 months, uncontrolled cardiac arrhythmia, or New York Heart Association Class III or IV), or severe debilitating pulmonary disease, that would potentially increase patients' risk for toxicity.
- Active heart disease including myocardial infarction within the previous 6 months, symptomatic coronary artery disease, abnormal ECG, or symptomatic congestive heart failure.
- Any active uncontrolled bleeding, or any patients with a bleeding diathesis (e.g., active peptic ulcer disease).
- Dyspnea with minimal to moderate exertion. Patients with large pleural, pericardial, or peritoneal effusions.
- Evidence of active infection, or serious infection within the past month.
- Patients with active central nervous system (CNS) or epidural solid or hematologic tumors.
- Patients receiving any standard or investigational therapy for any tumor indication within the past 2 weeks, or any investigational agent for any indication within the past 4 weeks, prior to the study.
- Patients who have received immunotherapy of any type for any indications within the past 4 weeks prior to the study.
- Ongoing oral corticosteroids are not permitted. However, topical and inhaled corticosteroids are permitted, and prophylactic steroids are allowed for transfusion reactions.
- Life expectancy less than 2 months.
- Pregnant women, or women of child-bearing potential not using reliable means of contraception.
- Lactating females.
- Fertile men unwilling to practice contraceptive methods during the study period.
- Unwillingness or inability to follow protocol requirements.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: CPI-613
CPI-613 will be intravenously infused over 2 hours, given twice weekly for 3 weeks followed by a week of rest.
|
CPI-613 drug product, provided in concentrated form at 50 mg/mL, must be diluted with D5W prior to administration.
CPI-613 is to be infused intravenously (IV) via a central venous catheter.
The dose of CPI-613 will be either the Maximum Tolerated Dose (MTD) or the highest No-Significant- Adverse-Effects-Dose-Level (NOAEL), as determined from the nearly completed Phase 1 dose-escalation clinical trial in patients with hematologic malignancies (i.e., Cornerstone Study# CL-CPI-613-009 or Wake Forest Study# CCCWFU 29109, under IND 107,800).
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Overall Survival (OS)
Time Frame: Monitored until participants passed away, for an expected average of 6 months.
|
Monitored until participants passed away, for an expected average of 6 months.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Remission Rate
Time Frame: Monitored at the end of every 4-week treatment cycle during treatment with CPI-613, for an expected average of 20 weeks.
|
Monitored at the end of every 4-week treatment cycle during treatment with CPI-613, for an expected average of 20 weeks.
|
|
Response Rate
Time Frame: Monitored at the end of every 4-week treatment cycle during treatment with CPI-613, for an expected average of 20 weeks.
|
Monitored at the end of every 4-week treatment cycle during treatment with CPI-613, for an expected average of 20 weeks.
|
|
Duration of Overall Remission
Time Frame: Monitored at the end of every 4-week treatment cycle during treatment with CPI-613, for an expected average of 20 weeks.
|
Monitored at the end of every 4-week treatment cycle during treatment with CPI-613, for an expected average of 20 weeks.
|
|
Progression Free Survival (PFS)
Time Frame: Monitored during treatment with CPI-613 and until participants passed away, which will be an expected average of 6 months.
|
Monitored during treatment with CPI-613 and until participants passed away, which will be an expected average of 6 months.
|
|
Quality of Life (QOL)
Time Frame: Monitored before, during and 1 week after treatment with CPI-613, for an expected average of 20 weeks.
|
Monitored before, during and 1 week after treatment with CPI-613, for an expected average of 20 weeks.
|
|
Safety
Time Frame: Monitored at the end of every 4-week treatment cycle during treatment with CPI-613, for an expected average of 20 weeks.
|
Safety assessment will be based on clinical signs, vital signs, blood work, adverse events, AEs, etc.
|
Monitored at the end of every 4-week treatment cycle during treatment with CPI-613, for an expected average of 20 weeks.
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: King C Lee, Ph.D., Cornerstone Pharmaceuticals
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CL-CPI-613-022 (Other Identifier: Protocol Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Myeloid Leukemia (AML)
-
Goethe UniversityCompleted
-
Daiichi Sankyo, Inc.CompletedAMLUnited States, Korea, Republic of, Taiwan, United Kingdom, France, Australia, Spain, Italy, Canada, Singapore, Germany, Netherlands, Hong Kong, Belgium, Croatia, Czechia, Hungary, Poland, Serbia
-
Gemin XCompleted
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.RecruitingNewly Diagnosed Acute Myeloid Leukemia (AML)China
-
Tarapeutics Science Inc.RecruitingRelapsed or Refractory Acute Myeloid Leukemia (AML)China
-
Zhejiang ACEA Pharmaceutical Co. Ltd.Recruiting
-
German Cancer Research CenterUniversity Hospital Heidelberg; University Hospital DresdenNot yet recruitingRelapsed/Refractory Acute Myeloid Leukemia (AML)Germany
-
Georgetown UniversityNational Heart, Lung, and Blood Institute (NHLBI); Jazz PharmaceuticalsRecruitingAcute Myeloid Leukemia (AML) in RemissionUnited States
-
The First Affiliated Hospital of Xiamen UniversityFujian Cancer Hospital; Huizhou Municipal Central Hospital; Chipscreen Biosciences... and other collaboratorsRecruitingLeukemia, Myeloid, Acute | AML Stage, AdultChina
-
The First Affiliated Hospital of Soochow UniversityRecruitingAcute Myeloid Leukemia (AML) in RemissionChina
Clinical Trials on CPI-613
-
Memorial Sloan Kettering Cancer CenterM.D. Anderson Cancer Center; Massachusetts General Hospital; City of Hope Medical... and other collaboratorsActive, not recruiting
-
Wake Forest University Health SciencesCompleted
-
Cornerstone PharmaceuticalsCompletedLymphoma | Metastatic Cancer | Advanced Cancer | Solid Tumors | Advanced MalignanciesUnited States, Canada
-
Medical College of WisconsinBarbara Ann Karmanos Cancer Institute; Cornerstone PharmaceuticalsRecruitingPancreas AdenocarcinomaUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Cornerstone PharmaceuticalsWithdrawnPancreatic Ductal Adenocarcinoma
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedAdvanced Adult Primary Liver Cancer | Localized Unresectable Adult Primary Liver Cancer | Recurrent Adult Primary Liver Cancer | Recurrent Extrahepatic Bile Duct Cancer | Unresectable Extrahepatic Bile Duct Cancer | Cholangiocarcinoma of the Extrahepatic Bile Duct | Cholangiocarcinoma of the Gallbladder and other conditionsUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)WithdrawnStage IV Non-Small Cell Lung Cancer AJCC v7 | Stage IIIB Non-Small Cell Lung Cancer AJCC v7United States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)TerminatedPreviously Treated Myelodysplastic SyndromesUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedRecurrent Small Cell Lung CancerUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedAcinar Cell Adenocarcinoma of the Pancreas | Duct Cell Adenocarcinoma of the Pancreas | Recurrent Pancreatic Cancer | Stage III Pancreatic Cancer | Stage IV Pancreatic CancerUnited States